CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 1, January – April 2024 62 AFRICA 93. Duvekot JJ, Roeters van Lennep JE. Searching for new biomarkers for preeclampsia: is there a role for corin? J Women’s Health 2015; 24(7): 546–547 94. Chen S, Sen S, Young D, Wang W, Moravec CS, Wu Q. Protease corin expression and activity in failing hearts. Am J Physiol Heart Circ Physiol 2010; 299(5): H1687–H1692. 95. Miyazaki J, Nishizawa H, Kambayashi A, Ito M, Noda Y, Terasawa S, et al. Increased levels of soluble corin in pre-eclampsia and fetal growth restriction. Placenta 2016; 48: 20–25. 96. Zhao S, Gu Y, Fan R, Groome LJ, Cooper D, Wang Y. Proteases and sFlt-1 release in the human placenta. Placenta 2010; 31(6): 512–518. 97. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005; 26(6): 1044–1059. 98. Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Molec Med 2010; 88(9): 889–897. 99. Zayed MA, Harring SD, Abendschein DR, Vemuri C, Lu D, Detering L, et al. Natriuretic peptide Receptor-C is up-regulated in the intima of advanced carotid artery atherosclerosis. J Med Surg Path 2016; 1(3). 100. Dong N, Zhou T, Zhang Y, Liu M, Li H, Huang X, et al. Corin mutations K317E and S472G from preeclamptic patients alert zymogen activation and cell surface targeting. J Biol Chem 2014; 289(25): 17909–17916. 101. Melchiorre K, Sutherland G, Sharma R, Nanni M, Thilaganathan B. Mid‐gestational maternal cardiovascular profile in preterm and term pre‐eclampsia: a prospective study. Br J Obstet Gynaecol 2013; 120(4): 496–504. 102. Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic structure and function in hypertensive disorders of pregnancy: a systematic review. Circ Cardiovasc Imaging 2016; 9(9): e004888. 103. Desai D, Moodley J, Naidoo D, Bhorat I. Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy. Br J Obstet Gynaecol 1996; 103(6): 523–528. 104. Naidoo D, Fayers S, Moodley J. Cardiovascular haemodynamics in pre-eclampsia using brain naturetic peptide and tissue Doppler studies. Cardiovasc J Afr 2013; 24(4): 130. 105. Bosio PM, McKenna PJ, Conroy R, O’Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94(6): 978–984. 106. Dennis A, Dyer R, Gibbs M, Nel L, Castro J, Swanevelder J. Transthoracic echocardiographic assessment of haemodynamics in severe pre‐eclampsia and HIV in South Africa. Anaesthesia 2015; 70(9): 1028–1038. 107. Kubis N, Levy B. Vasculogenesis and angiogenesis: molecular and cellular controls: part 1: growth factors. Intervent Neuroradiol 2003; 9(3): 227–237. 108. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J 1992; 6(3): 886–892. 109. Wimalasundera R, Larbalestier N, Smith J, De Ruiter A, Thom SM, Hughes A, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360(9340): 1152–1154. 110. Govender N, Naicker T, Moodley J. Maternal imbalance between proangiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia. Cardiovasc J Afr 2013; 24(5): 174. 111. Govender N, Naicker T, Rajakumar A, Moodley J. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia. Eur J Obstet Gynecol Repro Biol 2013; 170(1): 100–105. 112. Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1α expression and angiogenesis in glioblastoma cells. Neoplasia 2006; 8(11): 889–895. 113. Dhawan S, Puri RK, Kumar A, Duplan H, Masson J-M, Aggarwal BB. Human immunodeficiency virus-1–tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997; 90(4): 1535–1544. 114. Song L, Ding S, Ge Z, Zhu X, Qiu C, Wang Y, et al. Nucleoside/ nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells. Br J Pharmacol 2018; 175(8): 1241–1259. 115. Filardi PP, Paolillo S, Marciano C, Iorio A, Losco T, Marsico F, et al. Cardiovascular effects of antiretroviral drugs: clinical review. Cardiovasc Haematol Disord Drug Targets 2008; 8(4): 238–244. 116. Chai H, Yang H, Yan S, Li M, Lin PH, Lumsden AB, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquired Immune Def Syndr 2005; 40(1): 12–19. 117. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52(7): 569–576. 118. Savvidou M, Samuel M, Akolekar R, Poulton M, Nicolaides K. First trimester maternal uterine artery Doppler examination in HIV‐positive women. HIV Med 2011; 12(10): 632–636. 119. Sebitloane HM, Moodley D. The impact of highly active antiretroviral therapy on obstetric conditions: A review. Eur J Obstet Gynecol Repro Biol 2017; 210: 126–131. 120. Dosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocrine Rev 2005; 26(1): 44–62. 121. Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Human Repro Update 2012; 18(4): 458–471. 122. Smith C, Jalbert E, de Almeida V, Canniff J, Lenz LL, Mussi-Pinhata MM, et al. Altered natural killer cell function in HIV-exposed uninfected infants. Frontiers Immunol 2017; 8: 470. 123. Kottilil S. Natural killer cells in HIV-1 infection: role of NK cell-mediated non-cytolytic mechanisms in pathogenesis of HIV-1 infection. Indian J Exp Biol 2003; 41(11): 1219–1225. 124. Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, Lazanas M, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natn Acad Sci 2002; 99(10): 7015–7020. 125. Frias M, Rivero-Juarez A, Gordon A, Camacho A, Cantisan S, CuencaLopez F, et al. Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response. PLoS One 2015; 10(3): e0121019. 126. Laresgoiti-Servitje E, Gómez-López N, Olson DM. An immunological insight into the origins of pre-eclampsia. Human Repro Update 2010; 16(5): 510–524. 127. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Molec Endocrinol 2007; 21(11): 2785–2794. 128. Maharaj NR, Phulukdaree A, Nagiah S, Ramkaran P, Tiloke C, Chuturgoon AA. Pro-inflammatory cytokine levels in HIV infected and uninfected pregnant women with and without preeclampsia. PLoS One 2017; 12(1): e0170063. 129. Machado ES, Krauss MR, Megazzini K, Coutinho CM, Kreitchmann R, Melo VH, et al. Hypertension, preeclampsia and eclampsia among
RkJQdWJsaXNoZXIy NDIzNzc=